RICHMOND, Calif., Jan. 11, 2017 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced it will showcase its innovative EksoZeroG technology at the World of Concrete (WOC 2017) event January 17-20, 2017, in Las Vegas. The EksoZeroG, a lightweight assistive device for industrial workers, provides an exciting new solution to enhance productivity and workmanship as well as to reduce work-related injuries on construction sites.
“EksoZeroG is the first product in an industrial line that is a strategic priority for Ekso Bionics. The industrial product portfolio seeks to leverage our broad intellectual property, engineering expertise and extensive field testing with key industrial partners,“ said Tom Looby Chief Executive Officer.
Ekso Works, the industrial division of Ekso Bionics, produces the EksoZeroG, which is a versatile, lightweight device that easily mounts to aerial work platform rails or scaffolding and has multiple tool holders to accommodate a wide range of tools. The technology, which is designed to hold heavy tools and thereby offset the direct load from the tool operator, flexes effortlessly, easily following directional guidance during work.
“We are committed to developing innovative technology that makes it easier and safer for skilled workers to continue doing their jobs on construction worksites,” said Russ Angold, Co-Founder and Chief Technology Officer, Ekso Bionics. “EksoZeroG technology has been specifically designed to amplify workers by bearing the weight of heavy construction tools, such as rotary hammers and pneumatic chipping guns, during operation. This assistive technology reduces fatigue and injury risk for workers and can increase productivity during these heavy duty applications. Our ultimate goal is to keep workers healthy, happy and productive.”
The Ekso Bionics industrial product line seeks to address one of the biggest challenges facing the construction industry today – protecting workers while finishing jobs on time and within budget. Many companies are seeing a trend of increasing costs related to worker safety, driven primarily by worker fatigue, strain and other job-related injuries. With Ekso Bionics’ innovative technology, workers can complete heavy tool tasks with less fatigue, better workmanship and fewer workplace injuries.
At the Ekso Bionics outdoor booth, #O30608, visitors are invited to try the EksoZeroG and experience for themselves how this innovative technology can significantly help workers in this field.
To learn more about EksoZeroG, visit www.eksobionics.com and connect with us on LinkedIn, Facebook, Twitter, and YouTube.
About World of Concrete
World of Concrete is the industry’s only annual international event dedicated to the commercial concrete and masonry construction industries showcasing leading industry suppliers featuring innovative products, construction machinery, construction equipment, safety training courses, new technologies and unlimited networking opportunities to give you new ways to sustain and grow your business.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable exoskeletons available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing to fund the Company’s operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company’s products, the Company’s failure to achieve broad market acceptance of the Company’s products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure to obtain or maintain patent protection for the Company’s technology, failure to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact: Carrie Yamond/Glenn Silver 646-871-8485 email@example.com Investor Contact: Debbie Kaster 415-937-5403 firstname.lastname@example.org
Latest posts by Nasdaq NewsFeed (see all)
- Nokia debuts expanded portfolio of consumer digital health products and solutions - February 26, 2017
- Latvijas Juras medicinas centrs JSC: Consolidated interim report for the 12 months of 2016. - February 26, 2017
- Batelco selects Ericsson for mobile network enhancement - February 26, 2017